Ketotifen Sopharma 1 mg, 2p x 30 tablets — Made in Ukraine — Free Delivery

Pharmacodynamics. Ketotifen belongs to the group of cycloheptathiophenones and has a pronounced antihistamine effect. It belongs to the group of non-bronchodilating anti-asthma preparations. the mechanism of its action is associated with inhibition of the release of histamine and other mediators from mast cells, blocking histamine H1-receptors and inhibition of the enzyme pde, as a result of which the level of cAMP in mast cells increases. suppresses the effects of platelet-activating factor. when used independently, it does not stop attacks of ba, but prevents their appearance and leads to a decrease in their duration and intensity, and in some cases they completely disappear.

Pharmacokinetics. Resorption: characterized by almost complete resorption in the gastrointestinal tract. Cmax in blood plasma is reached after 2–4 hours. The equilibrium state is achieved after taking a minimum daily dose of 2 mg.

Distribution: binds to blood plasma proteins by about 75%. The volume of distribution is 2.7 l / kg of body weight.

Metabolism: about 60% of the dose taken is metabolized in the liver in three ways: demethylation, N-oxidation, N-glucuroconjugation, to such metabolites: ketotifen-N-glucuronide (pharmacologically inactive), nor-ketotifen (with pharmacological activity similar to that of unchanged ketotifen) , Ketotifen N-oxide and 10-hydroxy ketotifen (pharmacological activity unknown).

Excretion: excreted biphasic, with a short T1 / 2 (3-5 hours) and longer - 21 hours. About 1% of the substance is excreted unchanged in the urine within 48 hours, and 60-70% - in the form of metabolites.

Preventive treatment of ba, mainly of atopic form.

For the symptomatic treatment of allergic conditions, including allergic rhinitis and conjunctivitis.

The tablets are taken orally during meals with water.

Adults: 1 tablet (1 mg) 2 times a day in the morning and in the evening with meals. For patients who have a pronounced sedative effect, it is recommended to slowly increase the dose over the 1st week, starting from 0.5 mg 2 times a day until the therapeutic dose is gradually reached. If necessary, the daily dose can be increased to 4 mg (4 tablets) 2 times a day. When using the preparation at a higher dose, a more rapid onset of the therapeutic effect can be expected.

Children over the age of 3 years: 1 tablet (1 mg) 2 times a day in the morning and in the evening with meals.

Duration of treatment. The treatment is long-term, and the therapeutic effect is achieved after several weeks of therapy. Treatment should last at least 2-3 months, especially in patients who did not experience an improvement in their well-being in the first weeks of therapy. Concomitant bronchodilator therapy: Concomitant use of ketotifen with bronchodilators may reduce the frequency of bronchodilator use.

Termination of therapy. Discontinue treatment with ketotifen gradually, over 2-4 weeks, in order to avoid the risk of recurrence of asthmatic symptoms.

There are no special requirements for the elderly.

Hypersensitivity to the active or auxiliary substances of the preparation.

Breastfeeding period.

Infections and invasions

Uncommon - cystitis.

From the immune system

Very rarely - severe skin reactions, erythema multiforme, Stevens-Johnson syndrome.